These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 25908961)
1. Treating medullary thyroid cancer in the age of targeted therapy. Cabanillas ME; Hu MI; Jimenez C; Grubbs EG; Cote GJ Int J Endocr Oncol; 2014; 1(2):203-216. PubMed ID: 25908961 [TBL] [Abstract][Full Text] [Related]
2. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231 [TBL] [Abstract][Full Text] [Related]
3. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment. Dabelić N; Jukić T; Fröbe A Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884 [TBL] [Abstract][Full Text] [Related]
4. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes. Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907 [TBL] [Abstract][Full Text] [Related]
5. Role of vandetanib in the management of medullary thyroid cancer. Brassard M; Rondeau G Biologics; 2012; 6():59-66. PubMed ID: 22500115 [TBL] [Abstract][Full Text] [Related]
6. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia. Grasic Kuhar C; Lozar T; Besic N; Music Marolt M Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146 [TBL] [Abstract][Full Text] [Related]
7. Systemic treatment and management approaches for medullary thyroid cancer. Ernani V; Kumar M; Chen AY; Owonikoko TK Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392 [TBL] [Abstract][Full Text] [Related]
8. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Giunti S; Antonelli A; Amorosi A; Santarpia L Int J Endocrinol; 2013; 2013():803171. PubMed ID: 23509459 [TBL] [Abstract][Full Text] [Related]
9. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914 [No Abstract] [Full Text] [Related]
10. Recent Updates on the Management of Medullary Thyroid Carcinoma. Kim BH; Kim IJ Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449 [TBL] [Abstract][Full Text] [Related]